Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
MALVERN, Pa., April 19, 2018 -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its first quarter 2018 earnings on Wednesday, April 25 at 4:00 PM Eastern Time.
The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Wednesday, April 25, 2018. The broadcast will be available through the investor information section of the BioTelemetry website www.gobio.com. If you are unable to participate during the live webcast, an archive will be available on our website for two weeks.
About BioTelemetry
BioTelemetry, Inc., formerly known as CardioNet, Inc., is the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care. The Company currently provides cardiac monitoring services, original equipment manufacturing with a primary focus on cardiac monitoring devices and centralized cardiac core laboratory services. More information can be found at www.gobio.com.
Contact:
BioTelemetry, Inc.
Heather C. Getz
Investor Relations
800-908-7103
[email protected]
